Alireza Mansouri: What Does the Clinical Community vs General Public Think of GBM Clinical Trials?
Alireza Mansouri, Associate Professor at Penn State Health, shared a post on X:
‘Sharing a cool AI-powered project I did with Grok from xAI!
Request: Analyze public and scientific sentiment on clinical trials for Glioblastoma using X data. Break down by user type (general public vs. medical/scientific), exclude pharma conflicts and ads, plus word clouds.
Methodology: Used X semantic search to fetch ~80 relevant posts. Filtered out ads/pharma. Lexicon-based sentiment analysis (positive/negative words like ‘hope’ vs. ‘futile’). Categorized users via profiles. Word clouds from freq counts of key terms. All powered by Grok!
Results: The scientific community is more skeptical about trials than the general community!
General public (55 posts) – 65% positive (hope in immunotherapy/mRNA), 20% negative.
Scientific (25 posts) – 50% positive, 30% negative (critique on ethics/design).
Net positive overall! Key themes: breakthroughs vs. systemic issues.
Word clouds highlight ‘trial’, ‘hope’ For public; ‘survival,’ ‘unethical’ for scientists.”
More posts featuring Alireza Mansouri.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023